Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report

• Published in: Infection and drug resistance Vol. 15; pp. 5831 - 5838
• Main Authors: Fang, Changquan, Xu, Limin, Tan, Jiarong, Tan, Hongyi, Lin, Junhong, Zhao, Ziwen
• Format: Journal Article
• Language: English
• Published: Dove Medical Press Limited 31.10.2022; Dove; Dove Medical Press
• Subjects: Bacterial pneumonia; Case Report; Chlamydia; chlamydia psittaci; Diagnosis; Drug therapy; Health aspects; metagenomic next-generation sequencing; Methicillin; Multiple organ failure; omadacycline; Pneumonia; Psittacosis; Sulbactam; Zoonoses; China
• ISSN: 1178-6973; 1178-6973
• DOI: 10.2147/IDR.S384296

Psittacosis is a rare zoonotic disease caused by Chlamydia psittaci infection, and tetracyclines are the preferred treatment. Omadacycline is a novel tetracycline that has a strong in vitro antibacterial activity against atypical pathogens, including C. psittaci; however, clinical data for its usage are lacking. We report a patient with severe C. psittaci-induced pneumonia presenting with a high fever, muscle aches, severe hepatic and renal insufficiency, and acute respiratory failure requiring tracheal intubation and mechanical ventilation. The condition was diagnosed using metagenomic next-generation sequencing. The patient was discharged after treatment with omadacycline. The findings of this study suggest that metagenomic next-generation sequencing is valuable for the rapid and accurate diagnosis of psittacosis. With its good safety profile and no requirement for dose adjustment in special populations, omadacycline is a new option for the treatment of severe C. psittaci pneumonia. However, additional case reports are needed to support this conclusion. Keywords: Chlamydia psittaci, pneumonia, omadacycline, multiple organ failure, metagenomic next-generation sequencing